[Abstract Only] Randomized Trial: Treatments for Multiple Sclerosis Compared
15 Oct, 2019 | 08:35h | UTCSafety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial – The Lancet Neurology (link to abstract – $ for full-text)
Commentary: Measure From RADIANCE Data Suggests Ozanimod More Effective in Slowing MS Disease Activity – AJMC (free)
Source: EvidenceAlerts